Literature DB >> 18206714

Allergic rhinitis.

Richard W Weber1.   

Abstract

Allergic rhinitis is common malady with a significant impact on quality of life. It can affect 25% to 35% of people, depending on the population studied. Costs for physicians' visits and medications, and indirect costs of missed school and work and lost productivity, are estimated to be $2 billion annually in the United States. Pharmacotherapy is the most used therapeutic modality. Topical corticosteroids are the preferred method of treatment for seasonal and perennial allergic rhinitis. Antihistamines and antileukotrienes may be beneficial add-ons to topical steroids. Allergen avoidance is recommended, but may be difficult. Allergen immunotherapy is effective and should be considered with poor response to pharmacotherapy and avoidance.

Entities:  

Mesh:

Year:  2008        PMID: 18206714     DOI: 10.1016/j.pop.2007.09.001

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  9 in total

1.  Sub-lingual immunotherapy: world allergy organization position paper 2009.

Authors:  G Walter Canonica; Jean Bousquet; Thomas Casale; Richard F Lockey; Carlos E Baena-Cagnani; Ruby Pawankar; Paul C Potter; Philippe J Bousquet; Linda S Cox; Stephen R Durham; Harold S Nelson; Giovanni Passalacqua; Dermot P Ryan; Jan L Brozek; Enrico Compalati; Ronald Dahl; Luis Delgado; Roy Gerth van Wijk; Richard G Gower; Dennis K Ledford; Nelson Rosario Filho; Erkka J Valovirta; Osman M Yusuf; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2009-11-19       Impact factor: 4.084

2.  p38 MAPK regulates Th2 cytokines release in PBMCs in allergic rhinitis rats.

Authors:  Jie Liu; Lisi Liu; Yonghua Cui; Jian Zhang; Hongqun Jiang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-04-21

3.  Nuclear factor kappa B pathway down-regulates aquaporin 5 in the nasal mucosa of rats with allergic rhinitis.

Authors:  Weiwei Wang; Ming Zheng
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-05-21       Impact factor: 2.503

4.  Allergen immunotherapy: No evidence of infectious risk.

Authors:  Diana S Balekian; Aleena Banerji; Kimberly G Blumenthal; Carlos A Camargo; Aidan A Long
Journal:  J Allergy Clin Immunol       Date:  2016-04-09       Impact factor: 10.793

5.  Intranasal corticosteroids: do they improve ocular allergy?

Authors:  Catherine Origlieri; Leonard Bielory
Journal:  Curr Allergy Asthma Rep       Date:  2009-07       Impact factor: 4.806

6.  Sublingual immunotherapy: World Allergy Organization position paper 2013 update.

Authors:  Giorgio Walter Canonica; Linda Cox; Ruby Pawankar; Carlos E Baena-Cagnani; Michael Blaiss; Sergio Bonini; Jean Bousquet; Moises Calderón; Enrico Compalati; Stephen R Durham; Roy Gerth van Wijk; Désirée Larenas-Linnemann; Harold Nelson; Giovanni Passalacqua; Oliver Pfaar; Nelson Rosário; Dermot Ryan; Lanny Rosenwasser; Peter Schmid-Grendelmeier; Gianenrico Senna; Erkka Valovirta; Hugo Van Bever; Pakit Vichyanond; Ulrich Wahn; Osman Yusuf
Journal:  World Allergy Organ J       Date:  2014-03-28       Impact factor: 4.084

7.  Effects of rhinophototherapy on quality of life in persistant allergic rhinitis.

Authors:  Emel Çadalli Tatar; Hakan Korkmaz; Unzile Akpinar Sürenoğlu; Güleser Saylam; Ali Ozdek
Journal:  Clin Exp Otorhinolaryngol       Date:  2013-06-14       Impact factor: 3.372

8.  Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: A comparative study of efficacy and safety.

Authors:  Rituparna Maiti; Jyothirmai Jaida; Jalelur Rahman; Rajasri Gaddam; Anuradha Palani
Journal:  J Pharmacol Pharmacother       Date:  2011-10

9.  Allergic rhinitis: Disease characteristics and coping measures in Saudi Arabia.

Authors:  Abdulmohsin A Almehizia; Reema K AlEssa; Khalid M Alwusaidi; Khalid A Alzamil; Modhi AlJumah; Sarah Aljohani; Adel F Almutairi; Mahmoud Salam
Journal:  PLoS One       Date:  2019-06-26       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.